Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach
Jennifer Y. Sheng(Johns Hopkins University), Karen L. Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), John H. Fetting(Johns Hopkins University), Raquel Nunes(Harvard University), Antonio C. Wolff(Johns Hopkins University), Evanthia T. Roussos Torres(University of Southern California), Cesar A. Santa‐Maria(Johns Hopkins University), Haval Norman(Johns Hopkins University), Samantha R. Horn(Children's Hospital of Philadelphia), Lisa K. Jacobs(Johns Hopkins University), Vered Stearns(Johns Hopkins University), Rima Couzi(Johns Hopkins University), Christine Hodgdon(Patient-Centered Outcomes Research Institute), Neha Mangini, Elissa Thorner(Johns Hopkins University), Kala Visvanathan(Johns Hopkins University), Deborah K. Armstrong(Johns Hopkins University), Jessica Tao(Johns Hopkins University), Roisín M. Connolly(Johns Hopkins University), Mary Wilkinson(Johns Hopkins University), Jean L. Wright(University of North Carolina at Chapel Hill)
Cited by 67
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k